tiprankstipranks

Optinose downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Optinose (OPTN) to Neutral from Buy with a $9 price target after Paratek Pharmaceuticals announced it will be acquiring the company for $9 per share up front and contingent value rights worth up to $5 per share.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue